<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158727</url>
  </required_header>
  <id_info>
    <org_study_id>Cx611-0204</org_study_id>
    <nct_id>NCT03158727</nct_id>
  </id_info>
  <brief_title>Cx611-0204 SEPCELL Study</brief_title>
  <acronym>SEPCELL</acronym>
  <official_title>A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TiGenix S.A.U.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospital Regional Universitaire de Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellerix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa
      study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered
      intravenously as adjunctive therapy, therefore in addition to standard of care (SoC) therapy,
      to patients with severe community-acquired bacterial pneumonia (sCABP).

      The completion of this study will contribute to the basic knowledge on stem cells and their
      mode-of-action, and has a large translational character, i.e. to document the safety and
      explore the efficacy of Cx611 in patients with sCABP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa
      study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered
      intravenously as adjunctive therapy, therefore in addition to standard of care (SoC) therapy,
      to patients with severe community-acquired bacterial pneumonia (sCABP).

      The key objectives of this study are to:

      Primary objective:

      Investigate the safety profile of two allogeneic Cx611 central line 80 mL infusions within 3
      days (on days 1 and 3) at a dose of 160 million cells each (320 million cells total) and to
      monitor any adverse event and potential immunological host responses against the administered
      cells during 90 days of follow-up after the first infusion.

      Secondary objectives:

        1. Explore the clinical efficacy of Cx611 in terms of a reduction of the duration of
           mechanical ventilation and/or need for vasopressors and/or improved survival, and/or
           clinical cure of the sCABP, and other efficacy-related endpoints.

        2. Understand the mode-of-action of Cx611 in patients with sCABP by identifying the
           pro-inflammatory and anti- inflammatory pathways through which Cx611 may affect the
           underlying processes of sepsis.

        3. Follow-up safety (only SAEs) at months 6 and 12 after the first investigational
           medicinal product (IMP) dose administration (Day 1).

      Exploratory objective:

      Safety data collection (SAEs collection via phone calls) at months 18 and 24. The completion
      of this study will contribute to the basic knowledge on stem cells and their mode-of-action,
      and has a large translational character, i.e. to document the safety and explore the efficacy
      of Cx611 in patients with sCABP. The study results will be critical for the design of further
      confirmatory clinical trials in terms of definition of endpoints, key biomarkers and sample
      size determination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of 2 allogeneic Cx611 central line infusions at a dose of 160 million cells each</measure>
    <time_frame>90 days</time_frame>
    <description>Investigate the safety profile of 2 allogeneic Cx611 central line infusions within 3 days, at a dose of 160 million cells each and to monitor any adverse event and potential immunological host responses against the administered cells during 90 days of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of Cx611 in terms of a reduction of the duration of mechanical ventilation and/or vasopressors needed and/or improved survival, and/or clinical cure of the CABP, and other infection-related endpoints.</measure>
    <time_frame>90 days</time_frame>
    <description>Explore the clinical efficacy of Cx611 in terms of a reduction of the duration of mechanical ventilation and/or vasopressors needed and/or improved survival, and/or clinical cure of the CABP, and other infection-related endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Understand the mode-of-action of Cx611 in patients with sCABP</measure>
    <time_frame>90 days</time_frame>
    <description>Identifying the pro-inflammatory and anti- inflammatory pathways through which Cx611 may affect the underlying processes of sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety follow-up (SAEs only)</measure>
    <time_frame>at 6 and 12 months after Day 1</time_frame>
    <description>SAE collection</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Data Collection</measure>
    <time_frame>at 18 and 24 months</time_frame>
    <description>SAE collection via phone call</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Bacterial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Cx611</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cx611 Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Cx611 at a fixed dose of 160 million expanded allogeneic adipose-derived stem cells (eASCs) each</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Ringer Lactate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cx611 or Placebo</intervention_name>
    <description>Two intravenous infusions, one on day 1 and another one on day 3</description>
    <arm_group_label>Cx611</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Subjects of either sex aged ≥ 18 years and ≤ 80 years old.

          2. Body weight between 50 kg and 100 kg.

          3. Clinical diagnosis of acute (developed within ≤ 21 past days) community-acquired
             bacterial pneumonia based on the presence of two relevant signs (fever, tachypnea,
             leukocytosis, or hypoxemia) and radiographic findings of new pulmonary infiltrate/s.

          4. Subjects with pneumonia of sufficient severity requiring ICU management and with at
             least one of the two following major criteria of severity present for less than 18
             hours:

               1. Requiring invasive mechanical ventilation because of the pneumonia, or

               2. Requiring treatment with vasopressors (i.e., dopamine &gt;5 mg/kg/min or any dose of
                  epinephrine, norepinephrine, phenylephrine or vasopressin) for at least 2 hours
                  to maintain or attempt to maintain systolic blood pressure (SBP) &gt;90 mm Hg (or
                  mean arterial pressure (MAP) &gt;70 mm Hg) after adequate fluid resuscitation.

          5. Female subjects who are surgically sterile (e.g. 2-sided tubal resection or
             ovariectomy) or post-menopausal (history of no menses for at least 24 months) or Women
             of childbearing potential* must have negative serum or urine pregnancy test (sensitive
             to 25 IU human chorionic gonadotropin [hCG]). Sexually active women of childbearing
             potential must agree to use an adequate method of contraception for three months after
             the last dose of the investigational medicinal product. An adequate method of
             contraception is defined as sexual abstinence, adequate hormonal contraception (to
             have started at least 7 days prior to Screening visit), or an intra-uterine device (to
             have been in place for at least 2 months prior to Screening visit).

             *A woman of childbearing potential is sexually mature, has not undergone a
             hysterectomy or bilateral oophorectomy and has not been naturally postmenopausal for
             at least 24 consecutive months(i.e. has had menses at any time in the preceding 24
             consecutive months)&quot; or Male subjects agreeing to use condoms for three months after
             the last dose of the investigational medicinal product, or subjects having a partner
             who is using a highly efficient method of contraception as described above.

          6. Signed informed consent provided by the subject, the relatives or the designated legal
             representative according to local guidelines.

        Exclusion criteria

        A patient will not be included in the study if he/she meets ANY of the following criteria:

          1. Subjects with Hospital acquired-, Health Care acquired- or Ventilator
             associated-pneumonia.

          2. Subjects with pneumonia exclusively of viral or fungal origin*. Subjects with
             bacterial pneumonia co-infected with viruses and/or other microorganisms may be
             entered into the study.

             *Due to the short time window (up to 18 hours) between fulfilment of severity criteria
             (i.e. initiation of invasive mechanical ventilation or vasopressors administration,
             whichever comes first) and the start of the first dose of study treatment, patients
             with a pneumonia of suspected bacterial origin can be entered into the study
             (confirmation of bacterial origin must be obtained afterwards)

          3. Subjects with known or suspected Pneumocystis jirovecii (formerly known as
             Pneumocystis carinii) pneumonia.

          4. Subjects with an aspiration pneumonia.

          5. Subjects with known active tuberculosis.

          6. Subjects with a history of post-obstructive pneumonia.

          7. Subjects with cystic fibrosis.

          8. Subjects with any chronic lung disease requiring oxygen therapy at home.

          9. Presence of other infection (i.e. meningitis) caused by same pathogen.

         10. Subjects expected to have rapidly fatal disease within 72 hours after randomisation.

         11. Inability to maintain a mean arterial pressure ≥50 mmHg prior to Screening despite the
             presence of vasopressors and intravenous fluids.

         12. Subjects not expected to survive for 3 months due to other medical conditions such as
             end-stage neoplasm or other diseases.

         13. Subjects with primary or metastatic lung cancer and patients with anticipated
             chemotherapy within the next 90 days for any neoplastic syndrome.

         14. Subjects with known primary immunodeficiency disorder or with acquired immune
             deficiency syndrome (AIDS) with CD4 count &lt;200 cells/mm3 or not receiving highly
             active antiretroviral therapy (HAART).

         15. Subjects receiving immunosuppressant therapy (including chronic treatment with any
             anti-tumour necrosis factor alpha (TNFa) or on chronic high doses of steroids (single
             administration of ≥2 mg/kg body weight or 20 mg/day of prednisone or equivalent for ≥2
             weeks).

         16. Granulocytopenia, not due to sepsis, as evidenced by leukocyte absolute neutrophil
             count &lt;500 per µL.

         17. Haematopoietic and lymphoreticular malignancies, unless in remission.

         18. Subjects who received any stem cell, organ or bone marrow transplant within the past 6
             months.

         19. Subjects with ongoing treatment with a biological agent (e.g. antibodies, cells) or
             with plasma exchange treatment within the last 8 weeks.

         20. Subjects currently receiving, or having received another investigational medication
             within 90 days prior to start of the study (or 5 half-lives of the investigational
             compound, whichever is longer).

         21. Known allergies or hypersensivity to Penicillin or Streptomycin and/or any component
             of CryoStor CS10® (please refer to section 9.1.2)

         22. Subjects with a known liver function deficiency, e.g. associated with liver cirrhosis
             (Child PughC) or known oesophageal varices.

         23. Subjects hospitalised in previous 15 days

         24. Conditions resulting in a New York Heart Association Class IV functional status.

         25. End-stage neuromuscular disorders that impair weaning (e.g. amyotrophic lateral
             sclerosis).

         26. Patients with complete quadriplegia (traumatic or otherwise).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert SPAPEN, Prof.</last_name>
      <phone>+32 2 476 3085</phone>
      <email>Herbert.Spapen@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Herbert SPAPEN, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-François LATERRE, MD</last_name>
      <phone>+32 27 64 27 01</phone>
      <email>pierre-francois.laterre@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Pierre-François LATERRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard LAMBERMONT, MD</last_name>
      <phone>+3243667191</phone>
      <email>b.lambermont@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Bernard LAMBERMONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Pierre</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry DUGERNIER, MD</last_name>
      <phone>+32 1 043 71 23</phone>
      <email>thierry.dugernier@cspo.be</email>
    </contact>
    <investigator>
      <last_name>Thierry DUGERNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael MÁNEZ, MD</last_name>
      <phone>932607646</phone>
      <email>rmanez@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Rafael MÁNEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Mútua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique PIACENTINI, MD</last_name>
      <phone>93 736 50 50</phone>
      <email>epiacentini@mutuaterrassa.es</email>
    </contact>
    <investigator>
      <last_name>Enrique PIACENTINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raquel HERRERO, MD</last_name>
      <phone>91-683-9360</phone>
      <phone_ext>2397</phone_ext>
      <email>rherrero@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Raquel HERRERO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ángel LÓPEZ, MD</last_name>
      <phone>924 21 81 00</phone>
    </contact>
    <investigator>
      <last_name>Ángel LÓPEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricard FERRER, MD</last_name>
      <phone>93 274 62 09</phone>
      <email>r.ferrer@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Ricard FERRER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miquel FERRER, MD</last_name>
      <phone>93 227 5400</phone>
      <phone_ext>2015</phone_ext>
      <email>miferrer@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Miquel FERRER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni J. BETBESÉ, MD</last_name>
      <phone>93 553 72 38</phone>
      <email>ajbetbese@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Antoni J. BETBESÉ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes PALOMAR, MD</last_name>
      <phone>973 24 81 00</phone>
      <email>mpalomarmartinez@.com</email>
    </contact>
    <investigator>
      <last_name>Mercedes PALOMAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raúl de PABLOS, MD</last_name>
      <phone>913368159</phone>
      <email>raul.depablo.uah@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Raúl de PABLOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel SÁNCHEZ, MD</last_name>
      <phone>91.330.30.00</phone>
      <phone_ext>7214</phone_ext>
      <email>miguel.sanchez@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Miguel SÁNCHEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan C. MONTEJO, MD</last_name>
      <phone>91 3908907</phone>
      <email>juancarlos.montejo@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Juan C. MONTEJO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José M ANÓN, MD</last_name>
      <email>jmaelizalde@.com</email>
    </contact>
    <investigator>
      <last_name>José M ANÓN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borja SUBERVIOLA, MD</last_name>
      <phone>942202520</phone>
      <email>bsuberviola@.COM</email>
    </contact>
    <investigator>
      <last_name>Borja SUBERVIOLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Tarragona Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Rodríguez RÓDRIGUEZ, MD</last_name>
      <phone>977 295 818</phone>
      <email>ahr1161@.COM</email>
    </contact>
    <investigator>
      <last_name>Alejandro RÓDRIGUEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gonzalo Hernández, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gonzalo Hernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paula RAMÍREZ, MD</last_name>
      <phone>961244147</phone>
      <email>ramirez_pau@gva.es</email>
    </contact>
    <investigator>
      <last_name>Paula RAMÍREZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intensive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

